SCHEMBL22864441

SCHEMBL22864441

COC(=O)C1(c2c[nH]c3ccccc23)CC1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.51
CREBBP Q92793 1/20 0.51
MAPT P10636 5/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
DRD2 P14416 1/20 0.50
DRD4 P21917 1/20 0.50
DRD3 P35462 1/20 0.50
HDAC1 Q13547 1/20 0.49
PDE1C Q14123 1/20 0.45
SLC22A6 Q4U2R8 1/20 0.44
PBRM1 Q86U86 1/20 0.44
ALDH1A1 P00352 1/20 0.43
GPR84 Q9NQS5 1/20 0.42
ALOX5 P09917 1/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
KMT2A Q03164 1/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29800970 1.00 NR4A2 (0.51) NR4A2CREBBPMAPTSMN1; SMN2DRD2
SCHEMBL24814502 0.83 PBRM1 (0.51) NR4A2CREBBPMAPTSMN1; SMN2HDAC1
SCHEMBL22864574 0.82 NR4A2 (0.55) NR4A2MAPTALDH1A1
SCHEMBL30050333 0.81 HDAC1 (0.50) NR4A2MAPTSMN1; SMN2HDAC1PBRM1
SCHEMBL24812437 0.81 HDAC1 (0.50) NR4A2MAPTSMN1; SMN2HDAC1PBRM1
SCHEMBL3720163 0.80 ALDH1A1 (0.51) MAPTSMN1; SMN2HDAC1PBRM1ALDH1A1
SCHEMBL25139734 0.79 MAPT (0.47) MAPTSMN1; SMN2HDAC1PBRM1ALDH1A1
SCHEMBL30390141 0.75 HDAC1 (0.53) MAPTSMN1; SMN2HDAC1PBRM1ALDH1A1
SCHEMBL3243758 0.73 HDAC1 (0.55) MAPTSMN1; SMN2HDAC1PBRM1ALDH1A1
SCHEMBL3141852 0.73 TSHR (0.44) MAPTALDH1A1MEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023134608-A1 FUSED RING COMPOUNDS SERVING AS HPK1 INHIBITORS 微境生物医药科技(上海)有限公司 2023-07-20 WO disclosed
US-20220389037-A1 HPK1 INHIBITORS AND USES THEREOF REGOR PHARMACEUTICALS, INC. 2022-12-08 US disclosed
CN-114555585-A HPK1 inhibitors and uses thereof 上海齐鲁锐格医药研发有限公司 2022-05-27 CN disclosed
WO-2021000935-A1 HPK1 INHIBITORS AND USES THEREOF QILU REGOR THERAPEUTICS INC. (CN) 2021-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220389037-A1 HPK1 INHIBITORS AND USES THEREOF HIPK1, SIK1, PGK1 NR4A2 3976/4885CREBBP 1664/4885MAPT 3341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.